<DOC>
	<DOC>NCT00322595</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SRâ„¢ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Male or female aged 18 to 65 years; A diagnosis of generalized anxiety disorder; Absence of current episode of major depression. The presence or history of schizophrenia and other psychotic disorders; Hypertension; A current diagnosis of cancer, unless in remission for at least 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>GAD</keyword>
</DOC>